Cover Image
市場調查報告書

骨折:開發中產品分析

Bone Fracture - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 271824
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
骨折:開發中產品分析 Bone Fracture - Pipeline Review, H1 2016
出版日期: 2016年04月13日 內容資訊: 英文 84 Pages
簡介

所謂骨折,是受到超過骨組織強度的衝擊而造成骨頭斷裂。主要的症狀、跡象是骨折部位腫大,紫斑出現,手臂、骨頭變形,損傷的部分喪失功能,複雜骨折的情況是骨頭刺出皮膚等。

本報告提供全球各國的骨折治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

骨折概要

治療藥的開發

  • 骨折的開發中產品:概要
  • 骨折的開發中產品:比較分析

各企業開發中的骨折治療藥

大學/研究機關研究中的骨折治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

骨折治療藥:開發中的產品一覽(各企業)

骨折治療藥:研究中的產品一覽(各大學/研究機關)

骨折開發治療藥的企業

  • Arcarios BV
  • AstraZeneca Plc
  • Biogenomics Limited
  • BiologicsMD, Inc.
  • Biopharm GmbH
  • Bone Therapeutics SA
  • ethris GmbH
  • Juventas Therapeutics, Inc.
  • Kuros Biosciences AG
  • Novartis AG
  • TissueGene, Inc.
  • Viking Therapeutics, Inc.

骨折:治療藥的評估

  • 單劑治療藥的情況
  • 各標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • ALLOB
  • AZD-2858
  • bimagrumab
  • BMD-1221
  • Cyndacel-M
  • denosumab biosimilar
  • dibotermin alfa
  • Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture
  • Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders
  • Gene Therapy for Bone Fracture
  • JVS-200
  • KAL-436
  • KUR-111
  • KUR-113
  • LWnt-3a
  • Oligonucleotide to Activate BMP-2 for Bone Fracture
  • Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease
  • Recombinant Protein to Activate TNF-Alpha for Fracture Repair
  • Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders
  • Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders
  • Stem Cell Therapy for Fracture Repair
  • Synthetic Peptide for Osteoporosis and Bone Fracture
  • TG-B
  • VK-5211

骨折治療藥:開發中產品的最新趨勢

骨折治療藥:開發暫停的產品

骨折相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿(1件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7847IDB

Summary

Global Markets Direct's, 'Bone Fracture - Pipeline Review, H1 2016', provides an overview of the Bone Fracture pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bone Fracture, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bone Fracture
  • The report reviews pipeline therapeutics for Bone Fracture by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Bone Fracture therapeutics and enlists all their major and minor projects
  • The report assesses Bone Fracture therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Bone Fracture

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Bone Fracture
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bone Fracture pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bone Fracture Overview
  • Therapeutics Development
    • Pipeline Products for Bone Fracture - Overview
    • Pipeline Products for Bone Fracture - Comparative Analysis
  • Bone Fracture - Therapeutics under Development by Companies
  • Bone Fracture - Therapeutics under Investigation by Universities/Institutes
  • Bone Fracture - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Bone Fracture - Products under Development by Companies
  • Bone Fracture - Products under Investigation by Universities/Institutes
  • Bone Fracture - Companies Involved in Therapeutics Development
    • Arcarios BV
    • AstraZeneca Plc
    • Biogenomics Limited
    • BiologicsMD, Inc.
    • Biopharm GmbH
    • Bone Therapeutics SA
    • ethris GmbH
    • Juventas Therapeutics, Inc.
    • Kuros Biosciences AG
    • Novartis AG
    • TissueGene, Inc.
    • Viking Therapeutics, Inc.
  • Bone Fracture - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALLOB - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AZD-2858 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bimagrumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BMD-1221 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cyndacel-M - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • denosumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dibotermin alfa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Bone Fracture - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JVS-200 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KAL-436 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KUR-111 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KUR-113 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LWnt-3a - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide to Activate BMP-2 for Bone Fracture - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Activate TNF-Alpha for Fracture Repair - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Fracture Repair - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TG-B - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VK-5211 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Bone Fracture - Recent Pipeline Updates
  • Bone Fracture - Dormant Projects
  • Bone Fracture - Discontinued Products
  • Bone Fracture - Product Development Milestones
    • Featured News & Press Releases
      • Nov 03, 2015: Viking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture
      • Oct 20, 2015: Viking Therapeutics Completes Safety, Tolerability and Pharmacokinetic Study of VK5211, a Selective Androgen Receptor Modulator, in Healthy Elderly Subjects
      • Oct 09, 2015: Kuros Presents Results of Phase IIB Study with KUR-111 at the 2015 Orthopaedic Trauma Association Annual Meeting
      • Sep 01, 2015: Viking Therapeutics Initiates Clinical Trial for VK5211, a Selective Androgen Receptor Modulator, for Acute Hip Fracture
      • Jul 14, 2015: Viking Therapeutics Submits Investigational New Drug (IND) Application for VK5211, a Selective Androgen Receptor Modulator (SARM), in Acute Hip Fracture
      • Aug 29, 2013: Researcher Awarded $5 Million to Advance Future Stem Cell Treatments for Segmental Bone Fractures
      • Jan 24, 2011: Kuros Reports One Year Data From Phase IIb Study With KUR-111
      • Jun 02, 2010: Kuros Completes Patient Recruitment In A Phase IIB Trial Of KUR-113 In Patients With Tibial Shaft Fractures
      • Mar 15, 2010: Kuros Meets Primary Efficacy Endpoint In Phase IIb Study With KUR-111
      • Jun 08, 2009: Kuros Completes Patient Recruitment In A Phase IIb Trial Of KUR-111 In Patients With Tibial Plateau Fractures
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Bone Fracture, H1 2016
  • Number of Products under Development for Bone Fracture - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Bone Fracture - Pipeline by Arcarios BV, H1 2016
  • Bone Fracture - Pipeline by AstraZeneca Plc, H1 2016
  • Bone Fracture - Pipeline by Biogenomics Limited, H1 2016
  • Bone Fracture - Pipeline by BiologicsMD, Inc., H1 2016
  • Bone Fracture - Pipeline by Biopharm GmbH, H1 2016
  • Bone Fracture - Pipeline by Bone Therapeutics SA, H1 2016
  • Bone Fracture - Pipeline by ethris GmbH, H1 2016
  • Bone Fracture - Pipeline by Juventas Therapeutics, Inc., H1 2016
  • Bone Fracture - Pipeline by Kuros Biosciences AG, H1 2016
  • Bone Fracture - Pipeline by Novartis AG, H1 2016
  • Bone Fracture - Pipeline by TissueGene, Inc., H1 2016
  • Bone Fracture - Pipeline by Viking Therapeutics, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Bone Fracture Therapeutics - Recent Pipeline Updates, H1 2016
  • Bone Fracture - Dormant Projects, H1 2016
  • Bone Fracture - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Bone Fracture, H1 2016
  • Number of Products under Development for Bone Fracture - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top